Sethuraman Natarajan 4
4 · Entrada Therapeutics, Inc. · Filed Nov 13, 2024
Insider Transaction Report
Form 4
Sethuraman Natarajan
President, Research & Develop.
Transactions
- Sale
Common Stock
2024-11-11$20.01/sh−1,409$28,191→ 163,588 total - Sale
Common Stock
2024-11-13$20.04/sh−2,700$54,109→ 160,888 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.